Junshi Announces Successful Phase 3 NSCLC Study Results
Junshi Biosciences reported that its Phase 3 JS001sc-002-III-NSCLC study met primary endpoints, showing non-inferior drug exposure for subcutaneous toripalimab...
eClinical Tech News
Important New Elzonris Data Presented at Hematology Meeting
Menarini and Stemline will bring five ELZONRIS (tagraxofusp) data sets to ASH 2025, headlined by an oral Phase 2...
Cidara’s Phase 3 Flu Prevention Trial Hits Target Enrollment
Cidara completed enrollment of 6,000 participants in its Phase 3 ANCHOR trial of CD388, a single 450 mg subcutaneous...
New CREST-2 Study Confirms Carotid Stenting Benefits
In CREST-2, carotid artery stenting added to intensive medical therapy significantly reduced the composite of perioperative stroke or death...
Breakthrough Autism Drug ART-501 Positive in Phase 2 Trial
Four of six adults with autism spectrum disorder in a Phase 2a pilot study showed signs of clinical benefit...
FDA Accepts BLA Submission for ST-920 Fabry Disease Drug
In the Phase 1/2 STAAR study, isaralgagene civaparvovec (ST-920) generated a positive mean annualized eGFR slope at 52 weeks...
New Babesiosis Study Site Open for Enrollment at Mount Sinai
Phase 2 B-FREE will test a 12‑week tafenoquine regimen in up to 100 patients with chronic babesiosis, measuring change...
Cartesian’s SLE Trial Shows Strong Efficacy for Descartes-08
In an open-label Phase 2 study of systemic lupus erythematosus, Descartes-08 produced a 100% LLDAS response at Month 3...
Celcuity Submits New Breast Cancer Drug Application to FDA
The Phase 3 VIKTORIA-1 PIK3CA wild-type cohort reported a hazard ratio of 0.24 for the gedatolisib triplet (gedatolisib, fulvestrant,...
Pasithea’s NF1 Drug PAS-004 Shows Positive PK Data in Trial
PAS-004’s new tablet showed linear, dose-proportional PK with a long half-life (~57 hours) and tight peak–trough control at steady...